RetinAI collaboration with Heidelberg Engineering gives customers access to RetinAI’s analysis models in OCT

Latest press releases

RetinAI receives Innosuisse certificate

RetinAI Medical has received the prestigious Innosuisse Certificate of quality, which is awarded to Swiss startup companies ready for growth & scale-up.

RetinAI Announces Collaboration with Novartis to Provide Artificial Intelligence Solutions in Ophthalmology

RetinAI Medical AG announced a multi-year collaboration with Novartis Pharma AG under which RetinAI’s IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health.

RetinAI receives ISO 13485:2016 certification

RetinAI has just received the ISO 13485:2016 certification, an important recognition awarded by regulatory bodies and necessary for companies willing to develop and commercialise Medical Devices.

btov Partners leads CHF 2.3M investment into RetinAI to bring Artificial Intelligence to Health Data

RetinAI, a Bern based company building software tools to aggregate, manage, and analyse health data, has closed a CHF 2.3M pre-Series A financing round. btov Partners' Industrial Technologies Fund has led the round with participation of Swiss-based investor network Investiere and a consortium of selected private investors...

Latest updates

Fully-automated atrophy segmentation in dry age-related macular degeneration in optical coherence tomography - Scientific Reports

RetinAI is thrilled to introduce our novel method for the segmentation of atrophy with performance matching human experts published in Scientific Reports and developed in collaboration with the Fondation Asile des aveugles, Hôpital ophtalmique Jules-Gonin in Lausanne. Congratulations to both teams for this success!

Full Article - https://www.nature.com/articles/s41598-021-01227-0

Authors: Yasmine Derradji, Agata Mosinska, Stefanos Apostolopoulos, Carlos Ciller, Sandro De Zanet & Irmela Mantel Widmer

Automatic Atrophy Progression Prediction in Age-Related Macular Degeneration in EURETINA 2021

We are happy to present our novel method for prediction of continuous atrophy growth for follow-up periods of 4 years and longer in this year's EURETINA 2021. Congratulations to our collaborators and team members for this great poster.

We enable for the first time the creation of atrophy risk maps, which present the risk of retinal regions being affected by the atrophy in the future.

Authors: Agata Mosinska, Anthony Gigon, Stefanos Apostolopoulos, Carlos Ciller, Irmela Mantel Widmer, Sandro De Zanet

RetinAI in Top 100 Swiss Startups for 2021

RetinAI is proud to be recognized as one of the TOP 100 Swiss Startups for 2021. Check out the ‘Hall of Fame’ on www.top100startups.swiss to see Retinai again in the list this year.

Huge thanks to everyone in the team, to our supporters, and to our partners for believing in us along the way and for supporting us to define the future of Digital Precision Medicine!

First Peer-reviewed Publication around the RAZORBILL Study

The very first peer-reviewed publication around the RAZORBILL study has been published in the British journal of Ophthalmology (BJO).

'Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study'

A first of its class international multi-center clinical study to assess the influence of automated 3D OCT scan enrichment with segmentation information on disease activity assessment in patients with nAMD treated with either brolucizumab, ranibizumab or aflibercept.


We are glad to be supporting this initiative together with a leading team of world renown ophthalmologists & Novartis!

Contact us for more informations! We are happy to hear from you!